title: Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels.
abstract: BACKGROUND
  We previously demonstrated the therapeutic success of sequential boron neutron capture therapy (Seq-BNCT) in the hamster cheek pouch oral cancer model. It consists of BPA-BNCT followed by GB-10-BNCT 24 or 48 hours later. Additionally, we proved that tumor blood vessel normalization with thalidomide prior to BPA-BNCT improves tumor control. The aim of the present study was to evaluate the therapeutic efficacy and explore potential boron microdistribution changes in Seq-BNCT preceded by tumor blood vessel normalization.
  
  
  METHODS
  Tumor bearing animals were treated with thalidomide for tumor blood vessel normalization, followed by Seq-BNCT (Th+ Seq-BNCT) or Seq-Beam Only (Th+ Seq-BO) in the window of normalization. Boron microdistribution was assessed by neutron autoradiography.
  
  
  RESULTS
  Th+ Seq-BNCT induced overall tumor response of 100%, with 87 (4)% complete tumor response. No cases of severe mucositis in dose-limiting precancerous tissue were observed. Differences in boron homogeneity between tumors pre-treated and not pre-treated with thalidomide were observed.
  
  
  CONCLUSIONS
  Th+ Seq-BNCT achieved, for the first time, response in all treated tumors. Increased homogeneity in tumor boron microdistribution is associated to an improvement in tumor control.
authors: Department of Radiobiology, National Atomic Energy Commission (CNEA) , San Martin, Province Buenos Aires , Argentina.
authors: Ana J
authors: AJ
authors: Molinari
authors: Silvia I
authors: SI
authors: Thorp
authors: Agustina M
authors: AM
authors: Portu
authors: Gisela
authors: G
authors: Saint Martin
authors: Emiliano C C
authors: EC
authors: Pozzi
authors: Elisa M
authors: EM
authors: Heber
authors: Silva
authors: S
authors: Bortolussi
authors: Maria E
authors: ME
authors: Itoiz
authors: Romina F
authors: RF
authors: Aromando
authors: Andrea
authors: A
authors: Monti Hughes
authors: Marcela A
authors: MA
authors: Garabalino
authors: Saverio
authors: S
authors: Altieri
authors: Verónica A
authors: VA
authors: Trivillin
authors: Amanda E
authors: AE
authors: Schwint
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D001896:Boron Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D002273:Carcinogens; D006224:Cricetinae; D008647:Mesocricetus; D009062:Mouth Neoplasms / Q000098:blood supply / Q000139:chemically induced / Q000378:metabolism / Q000532:radiotherapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011230:Precancerous Conditions / Q000098:blood supply / Q000139:chemically induced / Q000378:metabolism / Q000532:radiotherapy; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D001896:Boron Compounds; D002273:Carcinogens; C569622:decahydrodecaborate; D010649:Phenylalanine; D013792:Thalidomide; D015127:9,10-Dimethyl-1,2-benzanthracene